Clinical Trial

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-28.
Trial Details
NCT Number NCT07568730
Lead Sponsor TearSolutions, Inc.
Conditions Neurotrophic Keratitis
Enrollment 54 participants
Start Date 2026-02-19
Primary Completion 2027-02 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-11